武田薬品工業株式会社
We would like to extend our heartfelt condolences to those who have been affected by the earthquake that occurred on January 1st, 2024 in Japan's Noto region and Ishikawa Prefecture.
We decided to donate JPY 10 million to Japanese Red Cross Society to support those who have been affected by the earthquake for ongoing relief and recovery efforts.
Additionally, we will further launch a matching gift campaign* together with our employees.
We will continue to support for those who have been affected by the earthquake in affected areas. We would like to again express our sincerest and most heartfelt wishes to those who have been affected by the earthquake, as well as our wishes for a swift relief and recovery of impacted areas.
*We and the Takeda Workers Union will have a joint donation campaign. Based on employees' donation, we will match employees' donation, additionally donating the same amount as employees donate.
Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries. For more information, visit www.takeda.com.